Trueheart, I agree. I am interested in revenues dictating success in this market. I realize others have their own plan or ideas, but I am with you. The only thing that will take SCRC to $4 is revenues. Celtics projection is based solely on revenues. The China market opening up with additional applications for RapiMeds could definintely accelerate revenues. The next several months for SCRC will tell the entire story.